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Abstract In recent years, more and more large, popula-
tion-level databases have become available for clinical
research. The size and complexity of these databases often
present a methodological challenge for investigators. We
propose that a ‘‘protocol’’ may facilitate the research pro-
cess using these databases. In addition, much like the
structured History and Physical (H&P) helps the audience
appreciate the details of a patient case more systematically,
a formal outcomes research protocol can also help in the
systematic evaluation of an outcomes research manuscript.
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Clinicians have an insatiable drive for deﬁnitive answers
regarding clinical judgments they make every day. They
also hold deep convictions based upon experience and
training, which can only be shaken (modiﬁed) by con-
vincing data. The days of relying upon the ‘‘chart review’’
for deﬁnitive answers has passed us by. How, then, can we
answer important clinical questions using current tools
from the rapidly developing world of outcomes research?
This requires the conversion of an interesting clinical
observation into an outcomes research question with a
testable hypothesis, followed by an outcomes analysis with
a research team.
The purpose of this article is to describe a ‘‘protocol,’’ or
pathway, to facilitate this process. Akin to the formal
method we teach new physicians to conduct a History and
Physical (H&P), a formal protocol such as described here
will facilitate outcomes analyses. There are three main
phases to the protocol: study design, data preparation, and
data analysis, with multiple steps within each phase. The
logic of the outcomes analysis process becomes clear if the
steps proceed sequentially.
Study design phase
The most important, and arguably the most difﬁcult, phase
of a study is its design phase. In fact, most problems with
research studies arise in the very ﬁrst step in this phase—
asking the research question. An improperly framed
research question will create difﬁcult problems throughout
the following steps of the project. Note that both the design
phase and the data preparation phase will comprise the
Methods section of a manuscript.
An important issue in framing a research question is:
Will it be a descriptive study or an analytical study? A
descriptive study is often employed when the research
question involves a rare or new occurrence, disease, or
procedure, since there is little established knowledge about
the topic. The hallmark of a descriptive study is questions
that begin with ‘‘what,’’ ‘‘where,’’ ‘‘when,’’ ‘‘who,’’ or
‘‘how.’’ For example, ‘‘Who has the disease in question?’’
or ‘‘What are the common comorbidities of patients with
the disease in question?’’ These are also known as ‘‘open-
ended’’ questions, and statistical testing is not applicable
since there is no a priori expectation of any particular
answer. If the study is descriptive, a statistician will not be
necessary.
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questions, usually beginning with a verb: ‘‘Is/Was…’’ or
‘‘Do/Does….’’ For example, ‘‘Does race or gender affect
the mortality of patients with the disease in question?’’
These studies call for a yes/no answer and statistical testing
is applicable.
The difference between open-ended questions for an
inquiry in its earliest stage versus closed-ended questions in
laterstagescanbecomparedtogatheringhistoryandphysical
examination information from a patient. A patient interview
begins with open-ended questions (‘‘Tell me about your
pain’’), but then moves on to closed-ended questions as the
matrix ofinformation beginsto createa picture ofthe clinical
situation. As this process evolves, the clinician begins to
formulate a differential diagnosis list (e.g., ‘‘Was it dull? Did
you have a fever? Was it in the left lower quadrant?’’).
Confusion arises when an attempt is made to compare
two slices of the same population with one another. For
example, if we want to know if there were more men or
women who underwent cholecystectomy last year, the
percentage of women versus men would be a descriptive
study and P values would not be relevant. This may appear
to be a comparative study, but in fact it is a descriptive
study because both populations (men who underwent
cholecystectomy and women who underwent cholecystec-
tomy) are correlated and thus represent the same popula-
tion. They are essentially ﬂip sides of the same coin.
Figure 1 may help to clarify. Note that in Fig. 1A there is
really only one pie, even though we have divided that pie
into multiple pieces (representing, e.g., male patients vs.
female patients). However, both slices of that pie are cal-
culated with the same denominator, i.e., patients who
underwent cholecystectomy. Any comparative statistics
about them would be descriptive and formal statistical
testing would not be applicable.
To change the above question from a descriptive ques-
tion to a ‘‘testable’’ question, we could, for example, ask
whether the male-to-female ratio has changed between last
year and the year before. Then one could calculate a
P value to compare the differences between the two ratios.
The P value in this instance would be interpreted as the
probability that the observed ﬁnding is based on random
chance alone, e.g., a P value of 0.05 indicates that in that
status quo one would see the results that were found only
5% of the time, and a P value of 0.01 indicates that one
would see the results that were found only 1% of the time,
and so on. Figure 1B shows that there are now two pies, so
we can ask whether the proportion of one group is higher or
lower in one pie than the proportion of that group in
another pie and determine the P value.
Step 1: deﬁne the population using inclusion
and exclusion criteria
Deﬁning the inclusion criteria for a study population is
usually fairly intuitive, but there are some nuances to
consider. For example, in examining the risk factors for
patient safety events in trauma patients, it may be obvious
that trauma patients should be the study population.
However, how should a trauma patient be deﬁned?
Depending on the database (as described below), the deﬁ-
nition of a trauma patient may be as simple as all patients
in the database if a trauma registry is active. However, it
may be more complicated if the database is a generic
database such as an administrative database. In such a case,
a set of diagnosis codes would be necessary to deﬁne
trauma patients (for trauma, it is diagnosis codes in the
range of 800-959).
However, not all ‘‘trauma’’ patients culled from an
administrative database would be pertinent to answering
the study question. This is where it becomes important to
craft appropriate exclusion criteria. These exclusion crite-
ria are usually related to the outcome variable or the
independent variable (outcome variable and independent
variable are deﬁned in more detail below). For example,
the risk factors for an event among patients who have the
condition already cannot be studied. If the development of
deep vein thrombosis (DVT) is to be studied, then patients
who are admitted with a DVT would need to be excluded.
Or, if the mortality rates of two treatment groups are to be
compared, then patients who present with that ‘‘condition,’’
Fig. 1 Conceptual illustration of the difference between a descriptive
and an analytical analysis. A depicts a descriptive study, where both
ratios are calculated off of the same denominator, and thus there is
really only one study population. No formal statistical testing is
applicable between 57 versus 43%. B depicts an analytical study,
where there are two different study populations (i.e., the 55% is
calculated off of a different denominator as the 57%). In that case,
formal statistical testing is applicable to compare 55 versus 57%.
A P value not applicable to compare different parts of the same
populations. B P value applicable for comparing parts of two
populations
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123i.e., dead on arrival, are excluded. In addition, the risk
factors cannot be studied in a population in which all
possible variations in the independent variable that you
want to test are not possible. For example, in the exami-
nation of the effect of insurance upon hospital admission
status, patients over age 65 would have to be excluded
since they are all insured and there are no uninsured
patients in that population. Importantly, patients may be
excluded for a combination of reasons. For example, burn
patients may be excluded from trauma populations because
the predictors of outcomes in burn patients are different
from those of most trauma patients [1].
The validity of a study depends in large part on how the
study population is deﬁned. Subtle differences in popula-
tion deﬁnition can produce different results. For example,
many administrative databases use the International Clas-
siﬁcation of Disease, Ninth Revision (ICD-9) coding sys-
tem to classify both diagnoses and procedures. Most
physicians in the United States are more familiar with the
American Medical Association’s Current Procedural Ter-
minology (CPT) system for classifying procedures and
think that the ICD-9 system pertains only to diagnosis
codes; however, there are ICD-9 diagnosis codes as well as
procedure codes. The difference between CPT and ICD
systems makes it difﬁcult to speciﬁcally identify certain
procedures since there are more CPT codes than ICD-9
procedure codes, with multiple procedures often lumped
into the same ICD-9 procedure code. Because of this
incongruity, seemingly disparate study ﬁndings may sim-
ply be due to different ICD-9 procedure codes having been
included in the inclusion criteria. To clarify such situations,
the list of exact diagnosis and/or procedure codes used in
the population deﬁnition should be included in the manu-
script, either in the Methods section or as a list in the
Appendix.
Step 2: deﬁne subsets
In outcomes research, an answer is often generated based
upon large heterogeneous populations. Subset analysis can
ask and answer questions about more homogeneous groups
(minorities, elderly, geographic area) within the larger set.
Thus, outcomes research is actually less effective in
showing that a treatment works when using a large popu-
lation (i.e., the efﬁcacy issue), since it is difﬁcult to control
for all possible confounders retrospectively in a database
[2]. Rather, the strength of outcomes research is in its
generalizability (i.e., whether the treatment works in real-
life situations and in every patient subpopulation). This has
also been labeled the ‘‘effectiveness’’ issue and makes
outcomes research an important tool for comparative
effectiveness research. For example, if ‘‘A’’ works overall,
does it also work in the elderly? Does it also work in
minority populations? The latter is especially an important
issue given the absence of data regarding minority popu-
lations in the literature [3, 4].
Step 3: deﬁne outcome variable(s)
This is perhaps the most important step in designing a
research question. Unfortunately, it is often inadequately
addressed, or missed entirely. It is quite typical for people
to ask, ‘‘What are the outcomes for xyz patients?’’ How-
ever, such a question does not specify what the target
outcome of interest actually is. An appropriate analytical
research question requires the outcome to be speciﬁed up
front: Is it mortality? Is it complications, or a speciﬁc set of
complications? Complications as an outcome is a perfect
example of why the outcome variable needs to be speciﬁed
up front: If you deﬁne ‘‘complication’’ to include only two
events, you will get a very different rate than if you
included ten events. Also, certain outcomes such as wound
infection or sepsis are notoriously difﬁcult to deﬁne.
If the question was properly framed in the beginning, as
a closed-ended question, then it usually becomes obvious
what the outcome variable is. Once again, the importance
of the initial framing of the question cannot be understated.
As described below, a study should have as few out-
comes as possible, so they must be chosen very carefully.
Each outcome of interest will require a fairly detailed
analysis on its own. Having multiple outcomes may make
the manuscript confusing. For example, the contributors
leading to DVT are likely to be different in the setting of
sepsis versus wound dehiscence versus death. A study that
attempts to examine all these different outcome variables is
likely to be lengthy and difﬁcult to digest.
Step 4: deﬁne the primary comparison to be made
This is a critical feature for any analytical study. In a
descriptive study, there is no comparison: The prevalence
of x and y and the average of z in that population are
simply described. An analytical study, on the other hand,
requires that some comparison be made. For example, the
question, ‘‘What is the mortality of xyz procedures in
elderly patients?’’ would be in a descriptive study where
statistical testing would not be applicable. The question,
‘‘Are the elderly at elevated risk for mortality compared to
younger patients following xyz procedure?’’ would be in a
comparative study where a statistical comparison would be
made between elderly patients and young patients. Speci-
fying the comparison to be tested up front also helps to
avoid Type I error; otherwise, the investigator runs the risk
of trying additional analyses, which may lead to spurious
ﬁndings.
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There are usually many factors that can inﬂuence an out-
come variable of interest: These are termed covariates and
confounders. For example, in comparing mortality rates of
patients, the inﬂuence of age, gender, race, socioeconomic
status, location, etc., must be considered in addition to the
primary comparison variable of interest. This highlights a
fundamental difference between clinical trials methodol-
ogy and outcomes research. Both are concerned with
confounders, but each addresses them differently. Clinical
trials methodology addresses the issue via randomization,
creating an equal mix of all possible confounders in both
comparison groups. Outcomes research, on the other hand,
does not have this luxury, and so it needs to adjust for the
inﬂuence of confounders statistically. This presents a
problem, however, since you need to know that something
is a confounder before you can add it to the analysis and
adjust for it. For example, if hair color were a determinant
of mortality, but we did not know this and thus it was not
collected and added to the database, then we would not be
able to adjust for it in the analysis. This is a major dif-
ference between outcomes research compared to clinical
trials, which is why this step is critical for outcomes
researchers. The strengths of an outcomes study depends
on how many covariates can be identiﬁed and adjusted for.
Data preparation phase
Once the research question is deﬁned, the next step is to
prepare the data for analysis. It is often surprising how long
and challenging this ‘‘data preparation’’ or ‘‘data cleaning’’
step can be. It is rare for an investigator to move straight
from the research question to an analysis without needing
to deeply analyze and qualify the relevant data. In addition,
it is important to take precaution at this phase to ensure
patient conﬁdentiality by not including patient identiﬁers in
the analytical ﬁle to be created. This issue may be less
relevant when analyzing administrative databases or pop-
ulation databases, but it may be overlooked when accessing
institutional clinical databases.
Note that both the design phase and the data preparation
phase will comprise the Methods section of a manuscript.
Step 1: select the database(s)
The ﬁrst step in the data preparation phase is to select the
workhorse database. Depending upon the research ques-
tion, an administrative database versus a clinical database
needs to be chosen. Also, the Agency for Healthcare
Research and Quality (AHRQ) offers a users’ guide to
registries that can be used to evaluate patient outcomes [5].
An example of an administrative database would be the
Nationwide Inpatient Sample (NIS) [6], which is effective
in answering questions regarding the cost of care. Exam-
ples of clinical databases would be the National Surgical
Quality Improvement Program (NSQIP) [7], the National
Trauma Data Bank (NTDB) [8], and the Surveillance,
Epidemiology, and End Results (SEER) database [9], all of
which contain more detailed clinical data. More than one
database may be suitable, or necessary, to address the
question at hand.
Step 2: link databases
The data that are needed to answer the research question
may reside in different databases, in which case the linking
of these databases will be necessary. This will require some
identiﬁers that are common in both databases; for example,
when looking at hospital characteristics (teaching status,
rural/urban location, volume) and their impact on patient
outcomes, the patient database will need to be linked with
the hospital database, probably via hospital identiﬁcation
numbers. For internal institutional databases, data are often
scattered across multiple data sources (medical records,
labs, radiology), and linking databases together with
patient identiﬁers becomes necessary. In most cases, the
need for identiﬁers to make this linkage will make it
impossible for investigators to act without help, especially
when dealing with population-level databases [10–12].
For example, since most population-level databases are
de-identiﬁed, it is not possible to link the SEER database
with NIS, which would be useful for answering questions
about hospital care versus long-term outcomes. Fortu-
nately, the federal government has recognized the need for
such a linked database and has now released the SEER
Medicare database for this purpose.
Step 3: select data elements
Selecting the data elements serves to match the research
question to the available data elements. This involves
looking up the reference manual, or ‘‘data dictionary,’’ for
each database, and matching the research question ele-
ments to their corresponding database deﬁnitions. This may
be challenging depending upon the clarity and rigor of the
particular database. For example, there are three different
variables for ‘‘stage of cancer’’ in the SEER database, all of
which use different criteria.
Step 4: generate new data elements
This is perhaps the most time-intensive phase of an out-
comes study. It is common for the sought variables to not
be deﬁned in a way that immediately meets the need of the
Surg Endosc (2011) 25:2254–2260 2257
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ments for the ‘‘stage’’ variable in SEER may not ﬁt the
assumptions of the study at hand. It then becomes neces-
sary to manually construct novel ‘‘stage’’ variables based
upon information from a number of other variables such as
‘‘extent of disease’’ or ‘‘node involvement,’’ This can
become even more difﬁcult if the variable of interest is
somewhat amorphous. For example, for any outcomes
study, it is important to adjust for patient ‘‘comorbidity.’’
However, there is no standard deﬁnition of comorbidity
that is universally accepted. To adjust for comorbidity
would therefore involve literature research to identify
possible methods to measure comorbidity (preferably
multiple methods) and then manually construct that vari-
able based on other information contained in the database
about each patient. In this speciﬁc case of comorbidity, the
Charlson Index [13, 14] or the Elixhauser Index [15]
among others would be useful.
Analysis phase
Following the process described below will produce the
Results section of the manuscript.
Step 1: univariate descriptive analysis
The univariate descriptive analysis describes the entire
study population. It is called ‘‘univariate’’ analysis because
the population is described one characteristic at a time:
average age, proportion males, race, socioeconomic status,
insurance status, location, and so on. This is important so
that future readers can determine whether the study applies
to their patients. Since this section is solely descriptive, no
formal statistical testing is necessary or applicable. An
example data table for a univariate analysis is presented in
Table 1. A study that is only descriptive would likely end
after this stage. Analytical studies will continue on through
the next few steps.
Step 2: bivariate analysis
The purpose of bivariate analysis is to report the differ-
ences between the comparison groups one characteristic at
a time. For example, in comparing elderly versus younger
patients, the data table will be a two-column table, with one
column for elderly and another column for younger
patients, and one row for every additional characteristic to
be compared. An example is presented in Table 2. At this
juncture, the task of statistical testing becomes central. If
the characteristic to be compared is a continuous variable
(e.g., length of stay), then t tests (for mean) or Wilcoxon
test (for median) can be applied [16]. If the characteristic to
be compared is a categorical variable (e.g., live or die),
then a v
2 test can be applied. If the outcome of interest is
survival over time, as is common in cancer research, then a
Kaplan–Meier analysis may be performed. The term
‘‘bivariate’’ analysis is used because for every statistical
test performed, the relationship between two variables (i.e.,
between age and death rates, then between age and length
of stay, and so on) is described statistically.
A clinical trial manuscript may end its Results section
here. It will not be necessary for it to go on to the multi-
variable analysis, since the comparison groups in a clinical
trial should be balanced in every way (if designed prop-
erly), and there is no reason to proceed further and adjust
for confounders. However, for outcomes analysis, the sta-
tistical tests presented in bivariate analysis are referred to
Table 1 Example of a univariate/demographics table
Age Median (IQR)
Gender
Male N,%
Female N,%
Ethnicity
White N,%
Black N,%
Hispanic N,%
Asian N,%
Intervention
Intervention A N,%
Intervention B N,%
Median length of stay in days (IQR) N (IQR)
Morbidity N,%
Mortality N,%
IQR interquartile range
Table 2 Example of a bivariate analysis data table, presenting
unadjusted comparison
Intervention A Intervention B
Age Median (IQR) Median (IQR) P = 0.ttt
Gender P = 0.ttt
Male N,% N,%
Female N,% N,%
Ethnicity P = 0.ttt
White N,% N,%
Black N,% N,%
Hispanic N,% N,%
Asian N,% N,%
Length of stay in days Median (IQR) Median (IQR) P = 0.ttt
Morbidity N,% N,% P = 0.ttt
Mortality N,% N,% P = 0.ttt
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made one variable at a time. This analysis will therefore
not account for any confounders, which are always present
in outcomes analysis.
Step 3: multivariable analysis
Multivariate analysis is the hallmark of outcomes research.
In a nutshell, it allows investigators to compare disparate
groups by mathematically adjusting the differences (i.e.,
the confounders) between comparison groups so that they
approach mathematical equivalence. Findings from multi-
variable analysis are also called ‘‘adjusted’’ results. An
example is presented in Table 3. Multivariate analysis is
performed with multiple logistic regression steps for a
categorical outcome variable (e.g., live or die) or with
multiple linear regressions for a linear outcome variable
(e.g., length of stay). If the outcome of interest is survival
over time, which is common in cancer research, then Cox
proportional hazards analysis will be used.
The validity of the results from an outcomes analysis
rests on the strength of this multivariable analysis—more
speciﬁcally, on the number of confounders accounted for in
this step. Therefore, it is important to list all the variables
that are included in a multivariable analysis, discuss the
rationale behind each of them, and then discuss these in the
‘‘limitations’’ part of the Discussion with respect to any
variable that could not be accounted for in the study. The
existence of unknown confounders should also be
acknowledged (unlike clinical trials, which theoretically
control for both known and unknown confounders via its
randomization process, the possibility exists in outcomes
analysis that there may be confounders that the world does
not yet know about).
Many outcomes analyses end here at the multivariable
analysis step. However, to make a stronger case, subset
analysis and sensitivity analysis should also be performed.
It will demonstrate appropriate rigor.
Step 4: subset analysis
The goal of subset analysis is to determine the generaliz-
ability of the ﬁndings. The idea is to repeat the analysis
within every patient subgroup to determine whether the
ﬁndings are qualitatively the same in all patients. These
subset analyses will eliminate the concern that the study
may be a spurious ﬁnding.
This is especially important in outcomes research, where
heterogeneous patients make up the study populations. For
example,ifAworksoverall,doesitalsoworkintheelderly?
Does it also work in minority populations? The consistency
of the ﬁndings across different patient subpopulations will
not only make the case for generalizability of ﬁndings, but it
will also address one of the fundamental limitations of out-
comesresearch:itsinabilitytoadjustforallconfounders.Ifa
ﬁnding is consistent across all patient populations, then the
unknown confounders are probably not an issue. Since the
prevalence of confounders is probably different in different
patient subgroups but the results are nevertheless qualita-
tivelyconsistentacrossthesegroups,thentheseconfounders
will likely not alter the study ﬁndings. There will obviously
be quantitative differences between different patient popu-
lations, so this effect will be stronger or weaker in different
patient subgroups. The objective of subset analysis (and the
next step, sensitivity analysis) is not to detect these minor
differences, but rather to detect whether there are qualitative
differences, i.e., are the ﬁndings reversed in any patient
subgroups. A few sentences regarding the presence or
absence of qualitative differences should sufﬁce.
Step 5: sensitivity analysis
The objective of sensitivity analysis is to alter some key
assumptions of the study to determine if those changes will
affect the conclusion. If the answer is no, it will strengthen
the case that the study is not affected by methodological
problems. Since there is often no consensus on what is the
‘‘best’’ methodology, a study that goes ahead and uses
multiple methodologies will eliminate any potential
reviewer concern that one method is better than another.
For example, if the data are adjusted for patient comor-
bidities with the Charlson Index, the analysis could be
repeated with the Elixhauser Index to determine if the
results change qualitatively. Another approach would be to
adjust for patient confounders with regular multiple
regression analysis, and then with propensity score analy-
sis, and see if the ﬁndings are equivalent [17, 18].
Table 3 Example of a multivariable analysis data table, showing
adjusted risks of outcome
Odds or hazard
ratio
95% CI P value
Age X.xx Y.yy–Z.zz 0.ttt
Gender
Male Reference
Female X.xx Y.yy–Z.zz 0.ttt
Ethnicity
White Reference
Black X.xx Y.yy–Z.zz 0.ttt
Hispanic X.xx Y.yy–Z.zz 0.ttt
Asian X.xx Y.yy–Z.zz 0.ttt
Intervention
Intervention A Reference
Intervention B X.xx Y.yy–Z.zz 0.ttt
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quantitative differences (e.g., the difference between
groups may be a little more or a little less), but hopefully
there will be no qualitative change in your conclusion. A
few sentences regarding the presence of absence of quali-
tative differences in the Discussion section should sufﬁce.
Conclusion
A methodical protocol such as the one described here can
facilitate converting an interesting clinical question into an
outcomes research question with a testable hypothesis.
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